CNTY-101 is under clinical development by Century Therapeutics and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CNTY-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CNTY-101 is under development for the treatment of relapsed and refractory B-cell non-Hodgkin lymphoma, follicular lymphoma, marginal zone lymphoma. The drug candidate is an allogeneic, iPSC derived CAR-iNK cell therapy that has been engineered to express chimeric antigen receptor (CAR) to target cells expressing CD19. It is developed based on iPSC derived Allo-Evasion technology. It is administered through intravenous route.
Century Therapeutics overview
Century Therapeutics is a pharmaceutical company. It develops curative allogeneic cell therapies for the treatment of cancer. The company’s major product portfolio includes CNTY-101; to treat B-cell malignancies, CNTY-103; to treat glioblastoma, CNTY-102; to treat B-cell malignancies, CNTY-104:to treat acute myeloid leukemia, CNTY-106; to treat multiple myeloma, TBD: to treat solid tumors, TBD: to treat hematological malignancies. It also offers cutting-edge gene editing, protein engineering, technical development, and manufacturing capabilities to generate allogeneic, iPSC-derived NK and T cell therapies for both hematological and solid tumor malignancies. The company is funded by Bayer and Leaps by Bayer, Versant Ventures, and Fujifilm Cellular Dynamics Inc. Century Therapeutics is headquartered in Philadelphia, Pennsylvania, the US.
For a complete picture of CNTY-101’s drug-specific PTSR and LoA scores, buy the report here.